As CEO of Lifebit working with 270M+ patient datasets across major pharma companies, the first thing I always verify is federated architecture implementation - specifically that data never leaves its original environment during processing. Most people focus on encryption or access controls, but the real vulnerability is data movement itself. We learned this the hard way during our early partnerships with NHS trusts. Traditional LLM platforms wanted to ingest our genomic data for processing, which would have violated GDPR and NHS data residency requirements instantly. One potential pharma client nearly walked away when they finded their previous AI vendor was copying patient data to third-party servers for model training. Our federated approach means the LLM runs where the data lives, not the other way around. When Genomics England processes COVID-19 research through our platform, their data stays in their infrastructure while our AI travels to them. This eliminated 80% of compliance headaches and prevented the data security incidents that hit 45% of organizations last year. The security control I double-check is simple: can I guarantee data residency? If the answer is no, we don't deploy. This saved us from multiple regulatory violations and is why government clients trust us with their most sensitive datasets.